iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today
reported its financial and operating results for the three months
ended March 31, 2023.
Highlights:
|
● |
Body of evidence supporting iCAD’s technologies grows, with
compelling new research supporting Company’s Breast AI Suite and
Xoft presented at key industry tradeshows and published in
peer-reviewed journals |
|
● |
Leadership team strengthened with seasoned executives poised to
accelerate key initiatives in the Company’s strategic
expansion |
|
● |
Company implemented a number of strategic changes, including
continued cost reduction measures to align and streamline cost
base, reducing annualized expenses by $4.3 - $4.6 million and
annualized cash burn by $4.9 - $5.2 million, putting Company on
track to achieve profitability exiting 2024 |
“We are making bold moves to rapidly transform this Company,
with a focus on preserving cash and building a defensible and
competitive long-term strategy that diversifies our revenue stream
and smooths out our customer concentration. Demand for our
technology continues to be strong and the body of evidence
supporting it continues to grow, with compelling new research
supporting ProFound AI Detection, ProFound AI Risk and the Xoft
System published in peer-reviewed journals and presented at key
industry tradeshows last quarter,” said Dana Brown, President and
CEO of iCAD, Inc.
“We are continuing to fortify our team with the addition of
several seasoned executives who will accelerate key initiatives in
the Company’s strategic plan, including forging new and strategic
relationships that will ensure our continued success, such as
partnerships with patient advocacy groups, pharmaceutical
companies, and payer organizations. I am confident that their
unique skillsets and contributions will be invaluable to our
progress, as we work to scale the impact of our AI solutions and
revolutionize patient care worldwide,” said Ms. Brown.
“With a continued focus on creating runway, preserving cash and
building a defensible and competitive long-term strategy, we are
currently going through a rigorous and thoughtful process to
evaluate a range of growth opportunities to diversify our revenue
stream and expand access to our technology to more customers and
patients worldwide. I remain optimistic about the Company and its
future, and I am confident that we are taking the right steps to
ensure continued growth and create additional shareholder value,”
said Ms. Brown.
Three Months Ended March 31, 2023 Financial
Results
Total Detection and Therapy revenue for the first quarter
of 2023 was $5.8 million, a decrease of $1.7 million, or
23%, as compared to the first quarter of 2022.
(in 000’s) |
|
Three months ended March 31, |
|
|
|
2023 |
|
|
2022 |
|
|
$ Change |
|
|
% Change |
|
Product revenue |
|
$ |
2,744 |
|
|
$ |
4,560 |
|
|
$ |
(1,816 |
) |
|
|
-39.8 |
% |
Service and supplies revenue |
|
|
3,034 |
|
|
|
2,963 |
|
|
|
71 |
|
|
|
2.4 |
% |
Total revenue |
|
$ |
5,778 |
|
|
$ |
7,523 |
|
|
$ |
(1,745 |
) |
|
|
-23.2 |
% |
Revenue: Cancer Detection revenue for the first quarter
of 2023, which includes the Company’s mammography and breast
density products, and the associated service and supplies revenue,
was $4.3 million, a decrease of 22%, as compared to the first
quarter of 2022. Therapy revenue for the first quarter
of 2023, which includes Xoft® Axxent® eBx® System® sales, as
well as the associated service and supplies revenue, was
$1.4 million, a decrease of 28%, as compared to the first
quarter of 2022.
(in 000’s) |
|
Three months ended March 31, |
|
|
|
2023 |
|
|
2022 |
|
|
$ Change |
|
|
% Change |
|
Detection revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue |
|
$ |
2,460 |
|
|
$ |
3,864 |
|
|
$ |
(1,404 |
) |
|
|
-36.3 |
% |
Service and supplies revenue |
|
|
1,874 |
|
|
|
1,657 |
|
|
|
217 |
|
|
|
13.1 |
% |
Detection revenue |
|
$ |
4,334 |
|
|
$ |
5,521 |
|
|
$ |
(1,187 |
) |
|
|
-21.5 |
% |
Therapy revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue |
|
$ |
284 |
|
|
$ |
696 |
|
|
$ |
(412 |
) |
|
|
-59.2 |
% |
Service and supplies revenue |
|
|
1,160 |
|
|
|
1,306 |
|
|
|
(146 |
) |
|
|
-11.2 |
% |
Therapy revenue |
|
$ |
1,444 |
|
|
$ |
2,002 |
|
|
$ |
(558 |
) |
|
|
-27.9 |
% |
Total revenue |
|
$ |
5,778 |
|
|
$ |
7,523 |
|
|
$ |
(1,745 |
) |
|
|
-23.2 |
% |
Gross Profit: Gross profit for the first quarter of 2023
was $4.1 million, or 71% of revenue, as compared to
$5.3 million, or 71% of revenue, in the first quarter of
2022.
Operating Expenses: Total operating expenses for the first
quarter of 2023 were $7.7 million, a 12% decrease from
$8.8 million in the first quarter of 2022.
GAAP Net Loss: Net loss for the first quarter of 2023 was
($3.8) million, or ($0.15) per diluted share, as compared to a
net loss of ($3.5) million, or ($0.14) per diluted share, for the
first quarter of 2022.
Non-GAAP Adjusted Net Loss: Non-GAAP
Adjusted Net Loss, a non-GAAP financial measure as defined below,
for the first quarter of 2023 was ($3.6) million, or ($0.14)
per diluted share, as compared to a Non-GAAP Adjusted Net Loss of
($3.5) million, or ($0.14) per diluted share, for the first quarter
of 2022. Please refer to the section entitled “Reconciliation of
Non-GAAP Financial Measures to Comparable GAAP Measures” and the
accompanying financial table included at the end of this release
for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss
results for the three-month periods ended March 31, 2023 and 2022,
respectively.
Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA, a non-GAAP
financial measure as defined below, for the first quarter
of 2023 was a loss of ($3.0) million compared to a loss of
$(2.7) million in the first quarter of 2022. Please refer
to the section entitled “Reconciliation of Non-GAAP Financial
Measures to Comparable GAAP Measures” and the accompanying
financial table included at the end of this release for a
reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA results
for the three-month periods ended March 31, 2023 and 2022,
respectively.
Conference Call Monday, May 15 at 4:30
PM ET
|
|
|
Domestic: |
|
877-545-0523 |
International: |
|
973-528-0016 |
Conference ID: |
|
380859 |
Webcast: |
|
https://www.webcaster4.com/Webcast/Page/2879/48223 |
Use of Non-GAAP Financial Measures
In its quarterly news releases, conference calls, slide
presentations or webcasts, the Company may use or discuss non-GAAP
financial measures as defined by SEC Regulation G. The GAAP
financial measures most directly comparable to each non-GAAP
financial measure used or discussed, and a reconciliation of the
differences between each non-GAAP financial measure and the
comparable GAAP financial measure, are included in this press
release after the condensed consolidated financial statements. When
analyzing the Company’s operating performance, investors should not
consider these non-GAAP measures as a substitute for the comparable
financial measures prepared in accordance with GAAP. The Company’s
quarterly news releases containing such non-GAAP reconciliations
can be found on the Investors section of the Company’s website at
www.icadmed.com.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology
leader providing innovative cancer detection and therapy solutions.
For more information, visit www.icadmed.com.
Forward-Looking
Statements Certain
statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
about the expansion of access to the Company’s products,
improvement of performance, acceleration of adoption, expected
benefits of ProFound AI®, the benefits of the Company’s products,
and future prospects for the Company’s technology platforms and
products. Such forward-looking statements involve a number of known
and unknown risks, uncertainties and other factors which may cause
the actual results, performance, or achievements of the Company to
be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. Such factors include, but are not limited, to the
Company’s ability to achieve business and strategic objectives, the
willingness of patients to undergo mammography screening in light
of risks of potential exposure to Covid-19, whether mammography
screening will be treated as an essential procedure, whether
ProFound AI will improve reading efficiency, improve specificity
and sensitivity, reduce false positives and otherwise prove to be
more beneficial for patients and clinicians, the impact of supply
and manufacturing constraints or difficulties on our ability to
fulfill our orders, uncertainty of future sales levels, to defend
itself in litigation matters, protection of patents and other
proprietary rights, product market acceptance, possible
technological obsolescence of products, increased competition,
government regulation, changes in Medicare or other reimbursement
policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed
in the Company’s filings with the Securities and Exchange
Commission. The words “believe,” “demonstrate,” “intend,” “expect,”
“estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and
similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking
statements, which speak only as of the date the statement was made.
The Company is under no obligation to provide any updates to any
information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the
disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at
http://www.sec.gov.
Media Inquiries:
Jessica Burns, iCAD+1-201-423-4492jburns@icadmed.com
Investor Inquiries:
iCAD Investor Relationsir@icadmed.com
|
|
iCAD, INC. AND SUBSIDIARIES Condensed
Consolidated Balance Sheets (In thousands, except for
share data)(Unaudited) |
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2023 |
|
|
2022 |
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
19,663 |
|
|
$ |
21,313 |
|
Trade accounts receivable, net of allowances for credit losses of
$922 as of both March 31, 2023 and December 31, 2022 |
|
|
7,381 |
|
|
|
8,898 |
|
Inventory, net |
|
|
4,866 |
|
|
|
5,389 |
|
Prepaid expenses and other current assets |
|
|
2,292 |
|
|
|
2,641 |
|
Total current assets |
|
|
34,202 |
|
|
|
38,241 |
|
Property and equipment, net of accumulated depreciation of $2,151
and 2,135 as of March 31, 2023 and December 31, 2022,
respectively |
|
|
1,153 |
|
|
|
1,074 |
|
Operating lease assets |
|
|
3,200 |
|
|
|
3,361 |
|
Other assets |
|
|
55 |
|
|
|
69 |
|
Intangible assets, net of accumulated amortization of $8,980 and
$8,932 as of March 31, 2023 and December 31, 2022,
respectively |
|
|
436 |
|
|
|
482 |
|
Goodwill |
|
|
8,362 |
|
|
|
8,362 |
|
Deferred tax assets |
|
|
111 |
|
|
|
116 |
|
Total assets |
|
$ |
47,519 |
|
|
$ |
51,705 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1,888 |
|
|
$ |
1,973 |
|
Accrued and other expenses |
|
|
4,213 |
|
|
|
4,681 |
|
Lease payable—current portion |
|
|
569 |
|
|
|
582 |
|
Deferred revenue—current portion |
|
|
6,211 |
|
|
|
6,216 |
|
Total current liabilities |
|
|
12,881 |
|
|
|
13,452 |
|
Lease payable, net of current |
|
|
2,639 |
|
|
|
2,803 |
|
Deferred revenue, net of current |
|
|
283 |
|
|
|
542 |
|
Deferred tax |
|
|
6 |
|
|
|
6 |
|
Total liabilities |
|
|
15,809 |
|
|
|
16,803 |
|
Commitments and Contingencies |
|
|
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value: authorized 1,000,000 shares; none
issued. |
|
|
— |
|
|
|
— |
|
Common stock, $0.01 par value: authorized 60,000,000 shares; issued
25,446,578 as of both March 31, 2023 and December 31, 2022 |
|
|
|
|
|
|
|
|
Outstanding 25,260,576 as of both March 31, 2023 and December 31,
2022 |
|
|
254 |
|
|
|
254 |
|
Additional paid-in capital |
|
|
303,485 |
|
|
|
302,899 |
|
Accumulated deficit |
|
|
(270,614 |
) |
|
|
(266,836 |
) |
Treasury stock at cost, 185,831 shares as of both March 31, 2023
and December 31, 2022 |
|
|
(1,415 |
) |
|
|
(1,415 |
) |
Total stockholders’ equity |
|
|
31,710 |
|
|
|
34,902 |
|
Total liabilities and stockholders’ equity |
|
$ |
47,519 |
|
|
$ |
51,705 |
|
|
|
iCAD, INC. AND SUBSIDIARIES Condensed
Consolidated Statements of Operations (In thousands,
except for per share data)(Unaudited) |
|
|
|
|
|
Three Months Ended |
|
|
|
March 31, |
|
|
|
2023 |
|
|
2022 |
|
Revenue: |
|
|
|
|
|
|
|
|
Products |
|
$ |
2,744 |
|
|
$ |
4,560 |
|
Service and supplies |
|
|
3,034 |
|
|
|
2,963 |
|
Total revenue |
|
|
5,778 |
|
|
|
7,523 |
|
Cost of revenue: |
|
|
|
|
|
|
|
|
Products |
|
|
586 |
|
|
|
1,087 |
|
Service and supplies |
|
|
993 |
|
|
|
1,049 |
|
Amortization and depreciation |
|
|
69 |
|
|
|
75 |
|
Total cost of revenue |
|
|
1,648 |
|
|
|
2,211 |
|
Gross profit |
|
|
4,130 |
|
|
|
5,312 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
Engineering and product development |
|
|
2,281 |
|
|
|
2,275 |
|
Marketing and sales |
|
|
2,857 |
|
|
|
3,565 |
|
General and administrative |
|
|
2,862 |
|
|
|
2,931 |
|
Amortization and depreciation |
|
|
55 |
|
|
|
63 |
|
Total operating expenses |
|
|
8,055 |
|
|
|
8,834 |
|
Loss from operations |
|
|
(3,925 |
) |
|
|
(3,522 |
) |
Other income/ (expense): |
|
|
|
|
|
|
|
|
Interest expense |
|
|
— |
|
|
|
(9 |
) |
Interest income |
|
|
150 |
|
|
|
— |
|
Other income (expense), net |
|
|
2 |
|
|
|
(13 |
) |
Loss on extinguishment of debt |
|
|
— |
|
|
|
— |
|
Other income (expense), net |
|
|
152 |
|
|
|
(22 |
) |
Loss before provision for income taxes |
|
|
(3,773 |
) |
|
|
(3,544 |
) |
Benefit (Provision) for tax expense |
|
|
(5 |
) |
|
|
(1 |
) |
Net loss and comprehensive loss |
|
$ |
(3,778 |
) |
|
$ |
(3,545 |
) |
Net loss per share: |
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.15 |
) |
|
$ |
(0.14 |
) |
Weighted average number of shares used in computing loss per
share: |
|
|
25,261 |
|
|
|
25,160 |
|
|
|
iCAD, INC. AND SUBSIDIARIES Condensed
Consolidated Statements of Cash Flows (In
thousands)(Unaudited) |
|
|
|
|
|
For the Three Months ended |
|
|
|
March 31, |
|
|
|
2023 |
|
|
2022 |
|
Cash flow from operating activities: |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(3,778 |
) |
|
$ |
(3,545 |
) |
Adjustments to reconcile net loss to net cash used for operating
activities: |
|
|
|
|
|
|
|
|
Amortization |
|
|
46 |
|
|
|
53 |
|
Depreciation |
|
|
78 |
|
|
|
86 |
|
Non-cash lease expense |
|
|
161 |
|
|
|
200 |
|
Bad debt provision |
|
|
— |
|
|
|
305 |
|
Stock-based compensation |
|
|
586 |
|
|
|
655 |
|
Deferred tax |
|
|
5 |
|
|
|
1 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
1,517 |
|
|
|
(1,723 |
) |
Inventory |
|
|
523 |
|
|
|
(565 |
) |
Prepaid and other assets |
|
|
363 |
|
|
|
653 |
|
Accounts payable |
|
|
(120 |
) |
|
|
(84 |
) |
Accrued and other expenses |
|
|
(468 |
) |
|
|
(514 |
) |
Lease liabilities |
|
|
(177 |
) |
|
|
(214 |
) |
Deferred revenue |
|
|
(264 |
) |
|
|
243 |
|
Total adjustments |
|
|
2,250 |
|
|
|
(904 |
) |
Net cash used for operating activities |
|
|
(1,528 |
) |
|
|
(4,449 |
) |
Cash flow from investing activities: |
|
|
|
|
|
|
|
|
Additions to patents, technology and other |
|
|
— |
|
|
|
(10 |
) |
Additions to property and equipment |
|
|
(122 |
) |
|
|
(151 |
) |
Net cash used for investing activities |
|
|
(122 |
) |
|
|
(161 |
) |
Cash flow from financing activities: |
|
|
|
|
|
|
|
|
Proceeds from option exercises pursuant to stock option plans |
|
|
— |
|
|
|
66 |
|
Proceeds from issuance of common stock pursuant to Employee Stock
Purchase Plans |
|
|
— |
|
|
|
60 |
|
Net cash provided by financing activities |
|
|
— |
|
|
|
126 |
|
(Decrease) increase in cash and cash equivalents |
|
|
(1,650 |
) |
|
|
(4,484 |
) |
Cash and cash equivalents, beginning of period |
|
|
21,313 |
|
|
|
34,282 |
|
Cash and cash equivalents, end of period |
|
$ |
19,663 |
|
|
$ |
29,798 |
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
|
|
Interest paid |
|
$ |
— |
|
|
$ |
9 |
|
Reconciliation of Non-GAAP Financial Measures to
Comparable GAAP Measures
The Company reports its financial results in accordance with
United States generally accepted accounting principles, or GAAP.
However, management believes that in order to understand the
Company’s short-term and long-term financial and operational
trends, investors may wish to consider the impact of certain
non-cash or non-recurring items, when used as a supplement to
financial performance measures in accordance with GAAP. These items
result from facts and circumstances that vary in frequency and/or
impact on continuing operations. Management also uses results of
operations before such items to evaluate the operating performance
of the Company and compare it against past periods, make operating
decisions, and serve as a basis for strategic planning. These
non-GAAP financial measures provide management with additional
means to understand and evaluate the operating results and trends
in the Company’s ongoing business by eliminating certain non-cash
expenses and other items that management believes might otherwise
make comparisons of the Company’s ongoing business with prior
periods more difficult, obscure trends in ongoing operations or
reduce management’s ability to make useful forecasts. Management
believes that these non-GAAP financial measures provide additional
means of evaluating period-over-period operating performance. In
addition, management understands that some investors and financial
analysts find this information helpful in analyzing the Company’s
financial and operational performance and comparing this
performance to its peers and competitors.
Management defines “Non-GAAP Adjusted EBITDA” as the sum of GAAP
Net Loss before provisions for interest expense, other income,
stock-based compensation expense, depreciation and amortization,
tax expense, severance, gain on sale of assets, loss on disposal of
assets, acquisition and litigation related expenses. Management
considers this non-GAAP financial measure to be an indicator of the
Company’s operational strength and performance of its business and
a good measure of its historical operating trends, in particular
the extent to which ongoing operations impact the Company’s overall
financial performance.
The non-GAAP financial measures do not replace the presentation
of the Company’s GAAP financial results and should only be used as
a supplement to, not as a substitute for, the Company’s financial
results presented in accordance with GAAP. The Company has provided
a reconciliation of each non-GAAP financial measure used in its
financial reporting and investor presentations to the most directly
comparable GAAP financial measure.
Management excludes each of the items identified below from the
applicable non-GAAP financial measure referenced above for the
reasons set forth with respect to that excluded item:
|
• |
Interest expense: The Company excludes interest expense which
includes interest from the facility agreement, interest on capital
leases and interest on the convertible debentures from its non-GAAP
Adjusted EBITDA calculation. |
|
• |
Stock-based compensation expense: excluded as these are non-cash
expenses that management does not consider part of ongoing
operating results when assessing the performance of the Company’s
business, and also because the total amount of expense is partially
outside of the Company’s control as it is based on factors such as
stock price volatility and interest rates, which may be unrelated
to our performance during the period in which the expense is
incurred. |
|
• |
Amortization and Depreciation: Purchased assets and intangibles are
amortized over a period of several years and generally cannot be
changed or influenced by management after they are acquired.
Accordingly, these non-cash items are not considered by management
in making operating decisions, and management believes that such
expenses do not have a direct correlation to future business
operations. Thus, including such charges does not accurately
reflect the performance of the Company’s ongoing operations for the
period in which such charges are incurred. |
|
• |
Severance and Furlough: The Company has incurred severance and
furlough expenses in connection with restructuring and in
connection with the separation of its former CEO. The Company
excludes these items from its non-GAAP financial measures when
evaluating its continuing business performance as such items
can vary significantly and do not reflect expected future operating
expenses. In addition, management believes that such items do not
have a direct correlation to future business
operations. |
|
• |
Loss on fair value of convertible debentures. The Company excludes
this non-cash item as it is not considered by management in making
operating decisions, and management believes that such item does
not have a direct correlation to future business operations. |
|
• |
Litigation related: These expenses consist primarily of settlement,
legal and other professional fees related to litigation. The
Company excludes these costs from its non-GAAP measures primarily
because the Company believes that these costs have no direct
correlation to the core operations of the Company. |
|
• |
Loss on extinguishment of debt: The Company excludes this non-cash
item as it is not considered by management in making operating
decisions, and management believes that such item does not have a
direct correlation to future business operations. |
On occasion in the future, there may be other items, such as
loss on extinguishment of debt, significant asset impairments,
restructuring charges or significant gains or losses from
contingencies that the Company may exclude if it believes that
doing so is consistent with the goal of providing useful
information to investors and management.
|
|
Non-GAAP Adjusted EBITDASet forth below is a reconciliation of the
Company’s “Non-GAAP Adjusted EBITDA”(Unaudited)(In thousands except
for per share data) |
|
|
|
|
|
Three Months Ended March 31, |
|
|
|
2023 |
|
|
2022 |
|
GAAP Net Loss |
|
$ |
(3,778 |
) |
|
$ |
(3,545 |
) |
Interest expense |
|
|
— |
|
|
|
9 |
|
Interest income |
|
|
(150 |
) |
|
|
— |
|
Other expense |
|
|
(2 |
) |
|
|
13 |
|
Stock compensation |
|
|
586 |
|
|
|
655 |
|
Depreciation & amortization |
|
|
124 |
|
|
|
139 |
|
Severance and Furlough |
|
|
172 |
|
|
|
— |
|
Tax expense |
|
|
5 |
|
|
|
1 |
|
Non-GAAP Adjusted EBITDA |
|
$ |
(3,043 |
) |
|
$ |
(2,728 |
) |
|
|
Three Months Ended March 31, |
|
|
|
2023 |
|
|
2022 |
|
GAAP Net Loss |
|
$ |
(3,778 |
) |
|
$ |
(3,545 |
) |
Adjustments to Net Loss: |
|
|
|
|
|
|
|
|
Severance and Furlough |
|
|
172 |
|
|
|
— |
|
Non-GAAP Adjusted Net
Loss |
|
$ |
(3,606 |
) |
|
$ |
(3,545 |
) |
Net Loss per share—basic and
diluted |
|
|
|
|
|
|
|
|
GAAP Net Loss per share |
|
$ |
(0.15 |
) |
|
$ |
(0.14 |
) |
Adjustments to Net Loss (as
detailed above) |
|
|
0.01 |
|
|
|
— |
|
Non-GAAP Adjusted Net Loss per
share |
|
$ |
(0.14 |
) |
|
$ |
(0.14 |
) |
Icad (NASDAQ:ICAD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Icad (NASDAQ:ICAD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024